文献速递肝病消化道肿瘤与早癌

miR-135a-5p介导的蛋白酪氨酸磷酸酶受体δ下调是HCV相关肝癌发生的候选驱动因素

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
PubMed 文献 · Gut · 2017-02-03

该研究通过分析原代人肝细胞、肝活检和肝癌切除标本的mRNA/miRNA表达谱及配对肝活检的微阵列和RNA-seq数据,发现HCV感染在体内和肝癌病灶中抑制肿瘤抑制因子PTPRD,且不依赖炎症或纤维化;瘤旁肝组织中高PTPRD水平与STAT3转录活性降低、患者生存改善及术后肿瘤复发减少相关,并鉴定miR-135a-5p为肝内PTPRD表达的机制性调控因子。作者结论为HCV通过上调miR-135a-5p抑制PTPRD,促进STAT3转录程序,存在可能驱动HCV相关肝病恶性进展的PTPRD-STAT3轴异常。

要点

  • HCV感染在体内和肝癌病灶中抑制PTPRD,且不依赖组织炎症或纤维化。
  • 瘤旁肝组织高PTPRD水平与STAT3转录活性降低、患者生存改善及术后复发减少相关。
  • miR-135a-5p被鉴定为HCV患者肝内PTPRD表达的机制性调控因子。

核心结论

  • HCV通过上调miR-135a-5p抑制其调控因子PTPRD,从而在患者肝脏中促进STAT3转录程序。
  • 研究结果提示存在可能驱动HCV相关肝病恶性进展的PTPRD-STAT3轴异常。

研究设计与样本

  • 研究评估了原代人肝细胞、患者肝活检和肝癌切除标本的mRNA和microRNA表达谱,并分析了肝癌患者配对肝活检的微阵列和RNA-seq数据。
  • 通过基因集富集分析揭示转录网络变化,并将磷酸酶表达水平与患者生存和肿瘤复发进行关联分析。

主要发现

  • HCV感染在体内和配对肝活检的肝癌病灶中抑制肿瘤抑制因子蛋白酪氨酸磷酸酶受体δ(PTPRD),且独立于组织炎症或纤维化。
  • 在瘤旁肝组织中,高PTPRD水平与STAT3转录活性降低、患者肝癌生存改善及手术切除后肿瘤复发减少相关。
  • miR-135a-5p被鉴定为HCV患者肝内PTPRD表达的机制性调控因子。

关键数值与推荐

  • 瘤旁肝组织中高PTPRD水平与STAT3转录活性降低相关。
  • 瘤旁肝组织中高PTPRD水平与患者肝癌生存改善相关。
  • 瘤旁肝组织中高PTPRD水平与手术切除后肿瘤复发减少相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HCV infection is a leading risk factor of hepatocellular carcinoma (HCC). However, even after viral clearance, HCC risk remains elevated. HCV perturbs host cell signalling to maintain infection, and derailed signalling circuitry is a key driver of carcinogenesis. Since protein phosphatases are regulators of signalling events, we aimed to identify phosphatases that respond to HCV infection with relevance for hepatocarcinogenesis. METHODS: We assessed mRNA and microRNA (miRNA) expression profiles in primary human hepatocytes, liver biopsies and resections of patients with HCC, and analysed microarray and RNA-seq data from paired liver biopsies of patients with HCC. We revealed changes in transcriptional networks through gene set enrichment analysis and correlated phosphatase expression levels to patient survival and tumour recurrence. RESULTS: We demonstrate that tumour suppressor protein tyrosine phosphatase receptor delta (PTPRD) is impaired by HCV infection in vivo and in HCC lesions of paired liver biopsies independent from tissue inflammation or fibrosis. In liver tissue adjacent to tumour, high PTPRD levels are associated with a dampened transcriptional activity of STAT3, an increase of patient survival from HCC and reduced tumour recurrence after surgical resection. We identified miR-135a-5p as a mechanistic regulator of hepatic PTPRD expression in patients with HCV. CONCLUSIONS: We previously demonstrated that STAT3 is required for HCV infection. We conclude that HCV promotes a STAT3 transcriptional programme in the liver of patients by suppressing its regulator PTPRD via upregulation of miR-135a-5p. Our results show the existence of a perturbed PTPRD-STAT3 axis potentially driving malignant progression of HCV-associated liver disease.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Van Renne N, Roca Suarez AA, Duong FHT, et al. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut. 2017. PMID: 28159835. doi:10.1136/gutjnl-2016-312270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。